Mereo BioPharma Q3 net loss narrows 17% to $5.86 million
MREO•Mereo BioPharma’s third-quarter 2026 net loss narrowed 17% year over year to $5.86 million. Revenue was $800,000, and the company reported $26.1 million in cash, expected to fund operations into late 2027.
1. Quarterly results and outlook
Mereo BioPharma reported a third-quarter 2026 net loss of $5.86 million, down 17% year over year. Revenue reached $800,000, while research and development expenses fell 51% to $2.09 million. Cash and cash equivalents totaled $26.1 million at September 30, which the company expects to fund operations into late 2027.
2. Drug program updates
Regulatory discussions with partner Ultragenyx continue to assess a potential path forward for setrusumab in pediatric osteogenesis imperfecta. Mereo is working with Sentynl to refine alvelestat’s Phase 3 trial design, with preparations targeting a potential early-2027 study launch.
